Overexpression of membrane-associated fatty acid binding protein (FABPpm) in vivo increases fatty acid sarcolemmal transport and metabolism

David C. Clarke,1 Dragana Miskovic,2 Xiao-Xia Han,1 Jorge Calles-Escandon,3 Jan F. C. Glatz,4 Joost J. F. P. Luiken,4 John J. Heikkila,4 and Arend Bonen5
1Departments of Kinesiology and 2Biology, University of Waterloo, Waterloo, Ontario N2L 3G1, Canada; 3Section of Endocrinology and Metabolism, Wake Forest University School of Medicine and Baptist Medical Center, Winston-Salem, North Carolina 27157; 4Department of Molecular Genetics, Maastricht University, 6200-MD Maastricht, The Netherlands; and 5Department of Human Biology and Nutritional Sciences, University of Guelph, Guelph, Ontario N1G 2W1, Canada

Submitted 12 November 2003; accepted in final form 19 December 2003

Clarke, David C., Dragana Miskovic, Xiao-Xia Han, Jorge Calles-Escandon, Jan F. C. Glatz, Joost J. F. P. Luiken, John J. Heikkila, and Arend Bonen. Overexpression of membrane-associated fatty acid binding protein (FABPpm) in vivo increases fatty acid sarcolemmal transport and metabolism. Physiol Genomics 17: 31–37, 2004. First published December 23, 2003; 10.1152/physiolgenomics.00190.2003.—Fatty acid translocase (FAT/CD36) is a key fatty acid transporter in skeletal muscle. We examined the functional effects of overexpressing FABPpm on the rates of 1) palmitate transport across the sarcolemma and 2) palmitate metabolism in skeletal muscle. One muscle (soleus) was transfected with pTracer containing FABPpm cDNA. The contralateral muscle served as control. After injecting the FABPpm cDNA, muscles were electroporated. FABPpm overexpression was directly related to the quantity of DNA administered. Electrotrofetraction (200 μg/muscle) rapidly induced FABPpm protein overexpression (day 1, +92%, P < 0.05), which was further increased during the next few days (days 3–7; range +142% to +160%, P < 0.05). Sarcolemmal FABPpm was comparably increased (day 7, +173%, P < 0.05). Neither FAT/CD36 expression nor sarcolemmal FAT/CD36 content was altered. FABPpm overexpression increased the rates of palmitate transport (+79%, P < 0.05). Rates of palmitate incorporation into phospholipids were also increased (+36%, as were the rates of palmitate oxidation (+20%). Rates of palmitate incorporation into triacylglycerol depots were not altered. These studies demonstrate that in mammalian tissue FABPpm overexpression increased the rates of palmitate transport across the sarcolemma, an effect that is independent of any changes in FAT/CD36. However, since the overexpression of plasma FABPpm (+173%) exceeded the effects of the rates of palmitate transport and metabolism, it appears that the overexpression of FABPpm alone is not sufficient to induce completely parallel increments in palmitate transport and metabolism. This suggests that other mechanisms are required to realize the full potential offered by FABPpm overexpression.

FATTY ACID UPTAKE into metabolically important tissues occurs, in part, via a protein-mediated transport system (for review see Refs. 5, 37). A number of long-chain fatty acid transporters have been identified, including fatty acid transport proteins 1–5 (19, 38), fatty acid translocase (FAT/CD36) (1), and plasma membrane-associated fatty acid binding protein (FABPpm) (22, 42). Studies in our laboratory (7, 6, 20, 31, 27, 28) and others (10, 16) have established that FAT/CD36 regulates fatty acid uptake into muscle, heart, and adipose tissue. Moreover, we have shown that the insulin- and contraction-induced translocation of FAT/CD36 from intracellular depots to the plasma membrane increases palmitate uptake into muscle and heart (6, 29, 30). Overexpression of FATP1 (38) and FABPpm in 3T3 fibroblasts (22) can increase long-chain fatty acid uptake into these cell lines, but evidence for comparable actions by these two proteins in metabolically important mammalian tissues is presently lacking.

FABPpm is a 43-kDa peripheral membrane protein that is identical to mitochondrial aspartate aminotransferase (mAspAT) (2, 8, 43). This protein is localized to the mitochondrion and the plasma membrane (9). 3T3 fibroblasts transfected with a cDNA for mAspAT express FABPpm and exhibit saturable fatty acid uptake (22). FABPpm is expressed in most mammalian tissues examined. But, FABPpm is more abundantly expressed in heart compared with skeletal muscle (7, 31), and this may indicate that FABPpm expression is closely associated with the differing requirements for fatty acid metabolism in these tissues (heart ≫ muscle). Although FABPpm expression is enhanced when the oxidative capacity of muscle is increased by exercise training (23), it is not known whether this FABPpm increase results in greater rates of fatty acid transport and metabolism. We have observed that changes in long-chain fatty acid uptake into skeletal muscle occur either when parallel changes occur in plasmalemmal FAT/CD36 and FABPpm (27, 41), or when only plasmalemmal FAT/CD36, but not plasmalemmal FABPpm, is upregulated (28). To date, there have been no reports in which rates of fatty acid transport have been altered in mammalian tissue when only FABPpm, but not FAT/CD36, is upregulated. This may indicate that FABPpm, while being a necessary component of the sarcolemmal fatty acid transport system (31, 45), may play only a cooperative role with other fatty acid transporters. Therefore, we hypothesized that increasing the expression of plasmalemmal FABPpm, in the absence of corresponding changes in FAT/CD36, would not increase the rate of palmitate transport into muscle.

In the present study, we have examined the role of FABPpm on palmitate transport, independent of FAT/CD36. For these purposes we transfected, in vivo, a single skeletal muscle (soleus) of mature laboratory rats with a plasmid vector con-
taining the FABPpm gene. Subsequently, we determined the effects of FABPpm protein overexpression on 1) the rates of palmitate transport into giant sarcolemmal vesicles and 2) on the rates of palmitate metabolism in intact skeletal muscle. The electroporation approach in the present study has several advantages, 1) protein overexpression is achieved rapidly, in vivo, in fully mature skeletal muscle, a metabolically important tissue, and 2) importantly, the contralateral soleus muscle in the same animal serves as control, and therefore many other possible confounding factors are controlled (e.g., substrate-endocrine milieu, dietary intake).

METHODS

Male Sprague-Dawley rats (~300 g) were used for all experiments. Animals were housed in a climate and temperature controlled room on a 12:12-h reverse light-dark cycle. Rat chow and water were available ad libitum. The FABPpm gene was overexpressed in mature rat soleus muscle by electroporation of the muscle (see below). Studies were performed to examine the effects of different amounts of FABPpm cDNA (100, 200, 400 μg/muscle) on FABPpm protein expression, the time course of overexpression (1, 3, and 7 days), and the plasmalemmal localization of FABPpm. In addition, we examined the effects of overexpressing FABPpm on the rates of palmitate transport into giant sarcolemmal vesicles and on the rate of palmitate metabolism in intact soleus muscles (see below). All experimental procedures were approved by the Committee on Animal Care at the University of Waterloo.

Subcloning and plasmid DNA preparation. Two types of plasmid DNA were used in the electroporation experiments, pTracer-CMV2 (6.2 kb, Invitrogen) and pTracer-FABPpm (7.5 kb). Plasmid DNA was isolated using alkaline lysis and purified by polyethylene glycol (PEG) precipitation (36). FABPpm cDNA in pBluescript KS (pBluescript-FABPpm) was kindly provided by Dr. A. Iriarte (University of Missouri). The FABPpm cDNA was originally derived from mAspAT precursor mRNA (33). Using the pBluescript-FABPpm as a template, polymerase chain reaction (PCR) was performed using 5′-CCGTCCTACGCAGCACCCATGCCTCC forward and 5′-CTCTGGTGATTACTTGAGCTGG reverse primers and Taq polymerase. The 27-nucleotide forward primer corresponded to nucleotide 72–99 of the published sequence (GenBank accession no. M18467) and was designed to incorporate the Kozak sequence. The 24-nucleotide reverse primer corresponded to nucleotide number 1390–1367 of the published sequence. The resulting 1.3-kb PCR product was ligated into the EcoRV restriction enzyme site of pTracer, after the addition of terminal thymidine monophosphate residues to the 3′-ends of the linearized pTracer (32). Competent DH5α Escherichia coli cells were transformed using a calcium chloride protocol and plated on agar plates. The cloned PCR product was verified by DNA sequencing (Core Sequencing Facility, York University, Toronto).

Electroporation of soleus muscle. Animals were anesthetized with Somnotol (intraperitoneal 6.5 mg/100 g body mass; MTC Pharmaceuticals, Cambridge, ON) and provided with an analgesic (Temgesic, subcutaneous 30 mg/100 g body mass; Reckitt and Colman Pharmaceuticals). Thereafter, the shaved, lower hindlimb was sterilized (iodine and 70% ethanol), and electrode conductivity gel was applied to the medial aspect of the hindlimb. The entire ventral surface of the soleus was freed while not disrupting the connective tissue that encapsulates the soleus. Plasmid DNA was injected using a short (1.25 cm) 27-gauge needle. The needle was initially inserted into the distal aspect of the belly of the muscle and was directed proximally, parallel to the orientation of the muscle fibers. Upon injection, the area around the needle tip would swell with fluid. The needle was then pushed further proximal into the muscle and injection continued. This was repeated until the DNA had been delivered. To establish the relationship between FABPpm overexpression, the concentration of DNA injected was varied (0.5, 1.0, 2.0 μg/μl). Subsequently, all experiments were conducted using a DNA concentration of 1.0 μg/μl. For experimental control, the plasmid pTracer, devoid of FABPpm cDNA, was also electroporated into soleus muscles. For all experiments a total volume of 200 μl was injected into the soleus muscle.

Immediately following the DNA injection, a pair of 0.8-cm diameter plate electrodes, attached to a set of ruled calipers (BTX, San Diego, CA), were applied over the soleus muscle. The electrode electrode was applied to the underside of the medial aspect of the hindlimb. Electroporation of the intact soleus muscle was performed as described by Mir et al. (34) (8 electric pulses: 200 V/cm, 1 Hz, 20 ms in duration) (ECM 830 Square Wave Electroporator; BTX). After the pulse delivery, the overlying superficial muscle was sutured, and the skin incision was closed. Muscle tissue was sampled either 1, 3, or 7 days after transfecting the tissue. Unless otherwise noted, muscles were rapidly frozen using precooled tongs and stored at −80°C.

Giant sarcolemmal vesicle preparation palmitate transport. Giant vesicles were prepared from rat soleus muscle as we have described in detail elsewhere (6, 7, 27, 28, 31). For these purposes three to four solei were pooled to obtain sufficient material for the palmitate transport studies and for Western blotting of the plasma membrane fraction of the vesicles. The time course of overexpression (1, 3, and 7 days) determined as we have previously reported (6, 7, 27, 28, 31). Briefly, unlabelled palmitate (Sigma-Aldrich, Mississauga, Ontario, Canada) and [3H]palmitate (0.3 μCi; Amersham Life Science, Oakville, Ontario) and [14C]mannitol (0.06 μCi, Amersham Life Science) in a 0.1% BSA KCl/MOPS solution were added to 40 μl of vesicles (~80 μg protein). The reaction was carried out at room temperature for 15 s. Palmitate uptake was terminated by addition of 1 ml ice-cold KC1/MOPS, containing 2.5 mM HgCl2, and 0.1% BSA. The sample was quickly centrifuged at maximal speed in a microcentrifuge for 1 min. The supernatant was discarded, and radioactivity was determined in the tip of the tube. Nonspecific uptake was measured by adding the stop solution to the membrane before the addition of the isotopes.

Palmitate metabolism in isolated soleus muscles. In control and transfected muscles we examined the metabolism of palmitate. For these studies we used procedures that we have reported previously (11, 12, 13, 24). Briefly, soleus muscle strips were preincubated (30°C) for 20 min, followed by a 60-min incubation period (30°C). The incubation medium contained 0.5 mM palmitate and 5 mM glucose, as well as 2 μCi of [1-14C]palmitate (Amersham Life Science). A layer of mineral oil prevented the escape of CO2 from the incubation buffer. Palmitate oxidation was determined by acidifying 0.5 ml of incubation buffer with 1.0 ml of 1 M H2SO4 in a sealed glass vial holding a suspended center well containing benzzenzium hydroxide to trap the CO2. To determine the radioabeled palmitate incorporation into intramuscular lipid pools, we used procedures that we (12) have previously described. Muscles were blotted and weighed, and homogenized in a tissue homogenizer in 1.5 ml of ice-cold 1.2 chloroform:methanol solution. Thereafter, an additional 0.5 ml of pure chloroform was added and samples were again homogenized. Connective tissue was removed, blotted, and weighed, then subtracted from the muscle wet weight. Muscle samples were then spotted on silica gel plates (Silica Gel GF, 250 μm; Analtech, Newark, DE), and resolved in solvent (60:40:4, heptane-isopropyl-ether-acetic acid) for 45 min. Plates were air-dried, sprayed with dichlorofluorescein dye (0.02% wt/vol in ethanol), and visualized under long-wave ultraviolet light. Individual lipid bands (phospholipids, triacylglycerols) were identified against known standards and marked on the plate with a scalpel and scraped into vials for liquid scintillation counting.

Southern and Northern blotting. Proteins were detected, after separation by SDS-PAGE, using Western blotting procedures that we have described in detail elsewhere (6, 7, 27, 28, 31). The FABPpm polyclonal antibody was produced in one our laboratories (J. Calles-
RESULTS

Surgery and electrotransfection had minor effects on the animals’ body weights, with only a 2–4% weight loss during the first 2 days, followed by normal weight gain thereafter. These changes are less marked than in other experiments involving surgical intervention of skeletal muscle (34–36). The metabolic profile of electrotransfected muscle showed a small significant decrease in ATP (−20%, \( P < 0.05 \)), creatine phosphate (−28%, \( P < 0.05 \)), and total creatine (−14%, \( P < 0.05 \)), and an increase in glycogen (+20%, \( P < 0.05 \)) (data not shown). Although a reduction in 3-HAD activity did occur (−36%, \( P < 0.05 \)), no changes were observed in the activities of phosphofructokinase and citrate synthase (\( P > 0.05 \), data not shown). Collectively, these data indicate that electrotransfection was well tolerated by the animals and caused only modest changes in some, but not all, markers of muscle metabolism.

**FABPpm in electrotransfected soleus muscle.** Successful electrotransfection of soleus muscle with the pTracer-FABPpm was indicated by the accumulation of the GFP reporter as detected by Western blotting (Fig. 1A). Electrotransfected muscle also resulted in an accumulation of FABPpm mRNA (Fig. 1B). The omission of much of the 5’ and 3’ untranslated region of FABPpm cDNA in pTracer-FABPpm allowed us to distinguish between endogenous FABPpm 2.4-kb mRNA and the shorter 1.9-kb transcripts derived from the plasmid vector.

FABPpm protein overexpression was directly related to the quantity of DNA administered (Fig. 2). In subsequent experiments 200 μg/muscle of FABPpm cDNA was used. There was a rapid increase in FABPpm protein over the course of 1 wk (Fig. 3A). After 1 day, FABPpm protein was increased +92% (\( P < 0.05 \)). Maximum overexpression occurred between 3 days (+160%, \( P < 0.05 \)) and 7 days (+142%, \( P < 0.05 \)) (Fig. 3A). Electrotransfection with pTracer alone resulted in a small upregulation of FABPpm (+18%, \( P < 0.05 \)) after 1 day. This did not increase further thereafter (\( P > 0.05 \), Fig. 3A) and was only a modest increase compared with the eightfold greater increase observed when pTracer-FABPpm was administered (Fig. 3). Importantly, the specificity of the FABPpm overexpression was demonstrated by the fact that the expression of other transport proteins (MCT1, FAT/CD36) and Cav-3 was not altered (Fig. 3B). Transfection of soleus muscle with FABPpm increased the total content of FABPpm (+142%) and its plasma-membrane content (+173%) to a similar extent (Fig. 4A). The activity of mAspAT was also increased (+42%, \( P < 0.05 \), data not shown).

Effects of FABPpm overexpression on palmitate transport and metabolism. In FABPpm-electrotransfected soleus muscles, the rate of palmitate transport into giant vesicles was...
increased by 79% \((P < 0.05, \text{Fig. 4}\)B). Since neither plasmalemmal FAT/CD36 \((P > 0.05, \text{Fig. 4}\)B) nor H-FABPc (data not shown) were altered in FABPpm-electrotransfected muscle, the increase in the rate of palmitate transport in these muscles was not attributable to these proteins.

Along with the increase in palmitate transport, palmitate metabolism was also increased in FABPpm-transfected soleus muscles. The rate of palmitate incorporation into phospholipids was increased by 36% \((P < 0.05, \text{Fig. 5}\)A). There was also a trend for an increase in the rate of palmitate oxidation \((+20\%, P = 0.08, \text{Fig. 5}\)C) in the muscles that overexpressed FABPpm. No change was observed in the rate of intramuscular palmitate incorporation into triacylglycerols \((\text{Fig. 5}\)B). These changes in palmitate metabolism were more modest than the increase in plasmalemmal FABPpm and the rates of palmitate transport.

**DISCUSSION**

These studies have shown that the expression of the fatty acid transporter FABPpm can be rapidly increased \((1–7 \text{ days})\), in mature skeletal muscle, in vivo. Because FABPpm was also targeted to the plasma membrane, we were able to determine the functional consequences of overexpressing this protein on palmitate transport and metabolism in skeletal muscle, a metabolically important tissue. Importantly, these are the first studies to demonstrate that the overexpression of only FABPpm, in vivo, is sufficient to increase the rates of palmitate transport into giant sarcolemmal vesicles. Moreover, selected aspects of palmitate metabolism were also increased in muscles that overexpressed FABPpm. Thus these studies establish a clear role for FABPpm in palmitate flux across the plasma
membrane in skeletal muscle, a process that also affects aspects of palmitate metabolism.

Electrotransfection of muscle has also been used by others to examine the function of specific genes (cf. Refs. 3, 26). The advantage of transfecting a single muscle with FABPpm is that 1) whole body fuel homeostasis is not altered and 2) the functional consequences of altered gene expression can be examined in isolated, mature skeletal muscles. In addition, since the contralateral muscle within the same animal serves as control, our approach also controlled for alterations in the substrate/endocrine milieu that might be occurring, as well as for possible alteration in food intake. The latter was not a problem as animals lost only minimal weight the first 2 days after surgery (<4%) and gained weight normally from day 3 onward. Variation in FABPpm overexpression was low, with coefficients of variation (100 coef. of variation) ranging in all experiments from 6.6–11.7%. This is well within the range for many other biochemical measurements. We elected to perform the functional assessments of FABPpm overexpression by administering 200 μg FABPpm cDNA/muscle, which led to a +142% increase in FABPpm protein. This allowed us to control the overexpression of FABPpm and induce increments that were eightfold greater than the nonspecific 18% increase in control experiments and well beyond the experimental variability of 6.6–11.7%. Thus electrotransfection provided a highly effective means by which to overexpress FABPpm in a controlled manner, in vivo.

Although we used mAspAT cDNA to transfect muscle, it has been shown that 3T3 fibroblasts transfected with a cDNA for mitochondrial aspartate aminotransferase express FABPpm (22). It is known that FABPpm and mAspAT are the same protein (2, 43), which does not require alternative splicing of the mRNA (8). Immunogold labeling studies have shown that mAspAT/FABPpm is localized to the mitochondria and to the plasma membrane, as well as other sites in a number of tissues (9). FABPpm assists with fatty acid uptake across the plasma membrane (22), whereas mAspAT binds to the inner mitochondrial membrane, where this protein binds to the α-keto-

Fig. 5. Effects of electrottransfection of soleus muscle with FABPpm cDNA on the rates of palmitate incorporation into phospholipids (PL, A) and intramuscular triacylglycerols (TAG, B) and on the rate of palmitate oxidation (C) in isolated, intact soleus muscles. Data are means ± SE; n = 4 muscles for each treatment. *P = 0.05, pTracer-FABPpm cDNA vs. control. There was a trend for an increased rate of palmitate oxidation, pTracer-FABPpm cDNA vs. control (P = 0.08).
uptake across the plasma membrane in skeletal muscle and heart is now a well-established process (5, 7, 31). But, the physical means by which FABPpm, and other proteins, bind and move fatty acids across the plasma membrane remains unknown.

A number of studies have also shown that fatty acid transport rates are regulated by other fatty acid transporters. In particular, FAT/CD36 is also a key fatty acid transporter in mammalian tissues such as heart, adipose tissue, and skeletal muscle. Expression of FAT/CD36 in Ob17Py fibroblasts increases fatty acid transport rates (21), and in transgenic mice, overexpression of FAT/CD36 in skeletal muscle increased palmitate oxidation during muscle contraction (20). A null mutation in FAT/CD36 reduced the uptake of fatty acids (10). In selected animal models (obese Zucker rats and streptozotocin-induced diabetes), in which plasmalemmal FAT/CD36, but not necessarily plasmalemnaal FABPpm, was increased, there were concomitant changes in rates of fatty acid transport (27, 28). These observations began to suggest that while FABPpm may be a necessary component of the sarcolemmal fatty acid transport system, this protein might play only a facilitatory role to FAT/CD36. However, the present studies demonstrate clearly that an increase in plasmalemmpal FABPpm alone, without a parallel increase in plasmalemmal FAT/CD36, can also result in an increased rate of fatty acid transport, although the rate of palmitate uptake was considerably less than the increase in plasmalemmal FABPpm.

The FABPpm-induced increase in palmitate transport also increased rates of fatty acid metabolism. Specifically, in transfected muscles, palmitate incorporation into phospholipids and palmitate oxidation were also increased. We (12) have previously shown that there is good relationship between palmitate uptake and metabolism, indicating that when more fatty acids enter the cell, the rates of fatty acid oxidation and esterification are increased. But, since, palmitate incorporation into triacylglycerols was not altered in the present study, the important implication is that an upregulation of FABPpm may not be associated with insulin resistance and type 2 diabetes, in which there is a gradual buildup of intracellular triacylglycerol deposits (14, 35). Conversely, therapies designed to inhibit the transport function of FABPpm might not be effective in preventing triacylglycerol accumulation in type 2 diabetic muscles and, hence, may not have an antidiabetic potential.

In the present studies the increase in plasmalemmpal FABPpm (+173%) exceeded the increase in palmitate transport (+79%) and in the rates of palmitate incorporation into phospholipids (+36%) and palmitate oxidation (20%). This suggests that the increase in FABPpm by itself is not optimally effective for increasing fatty acid transport and metabolism. We (31) have previously shown that fatty acid transport appears to involve the cooperation between FABPpm and FAT/CD36. In a rat heart muscle cell line (H9c2), fatty acid uptake was not increased when only FAT/CD36 was overexpressed, leading to the suggestion that a concomitant increase in FABPpm might also be necessary (46). The possible involvement of both FAT/CD36 and FABPpm in fatty acid oxidation is suggested by recent studies showing that FAT/CD36 is also found on the mitochondrial membrane (4), where mAspAT/FABPpm is also located (9). Thus conceivably FAT/CD36 and mAspAT/FABPpm might interact at this location to regulate fatty acid oxidation. Indeed, we have preliminary evidence for this (S. E. Campbell and A. Bonen, unpublished data). Thus the disparate increments observed in plasmalemmpal FABPpm and in the rates of palmitate transport and oxidation may indicate that while an increase in plasmalemmal FABPpm can facilitate increased rates of fatty acid transport and metabolism, the FABPpm increase by itself is not sufficient to realize the full potential for increasing fatty acid transport and metabolism.

In summary, the present studies have shown that the fatty acid transporter FABPpm can be rapidly overexpressed in a single rat skeletal muscle. Overexpression of FABPpm increased the sarcolemmal content of FABPpm, resulting in increased rates of fatty acid transport across the sarcolemma and fatty acid metabolism. These studies provide the first evidence that FABPpm overexpression in mammalian tissue can increase fatty acid transport, which results in an increase in fatty acid metabolism.

ACKNOWLEDGMENTS

Present address of D. C. Clarke: Dept. of Chemical and Biological Engineering, University of Colorado, Boulder, CO.

GRANTS

These studies were supported by grants form the Canadian Institutes of Health Research, the Natural Sciences and Engineering Research Council of Canada, and the Netherlands Heart Foundation (200.156). D. C. Clarke was supported by a postgraduate scholarship from the Natural Sciences and Engineering Research Council of Canada. J. F. C. Glatz is Netherlands Heart Foundation Professor of Cardiac Metabolism. J. J. F. P. Luiken is a recipient of a VIDI-Innovation Research Grant from the Netherlands Organization for Scientific Research (NOW-ZonMw Grant 016.036.305). A. Bonen and J. J. Heikila are Canada Research Chairs.

REFERENCES


